|4Nov 23, 10:22 AM ET

EndoChoice Holdings, Inc. 4

4 · EndoChoice Holdings, Inc. · Filed Nov 23, 2016

Insider Transaction Report

Form 4
Period: 2016-11-22
Gilreath Mark
DirectorSee remarks.
Transactions
  • Disposition to Issuer

    Common stock, par value $0.001 per share

    2016-11-22$8.00/sh74,755$598,0400 total(indirect: By Trust)
  • Disposition to Issuer

    Common stock, par value $0.001 per share

    2016-11-22$8.00/sh1,818$14,5440 total(indirect: By Daughter)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2016-11-224,5690 total
    Exercise: $2.83From: 2009-01-01Exp: 2019-01-01Common stock, par value $0.001 per share (4,569 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2016-11-22140,7390 total
    Exercise: $16.01Exp: 2025-08-14Common stock, par value $0.001 per share (140,739 underlying)
  • Disposition to Issuer

    Common stock, par value $0.001 per share

    2016-11-22$8.00/sh12,243$97,9440 total(indirect: By Trust)
  • Disposition to Issuer

    Common stock, par value $0.001 per share

    2016-11-22$8.00/sh789,270$6,314,1600 total
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2016-11-2271,6450 total
    Exercise: $5.31Exp: 2026-03-29Common stock, par value $0.001 per share (71,645 underlying)
  • Disposition to Issuer

    Common stock, par value $0.001 per share

    2016-11-22$8.00/sh3,200$25,6000 total(indirect: By Spouse)
Footnotes (5)
  • [F1]Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer.
  • [F2]The total direct shares shown includes 3,063 shares purchased in the issuer's employee stock purchase plan on June 30, 2016.
  • [F3]This option was cancelled pursuant to the Merger in exchange for a cash payment representing the difference between the exercise price of the option and the merger consideration of $8.00 per share.
  • [F4]Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger.
  • [F5]This option was cancelled pursuant to the Merger. Since the exercise price of this option exceeded the merger consideration of $8.00 per common shares, no cash payment was received by the reporting person.

Documents

1 file
  • 4
    wf-form4_147991451461000.xmlPrimary

    FORM 4